On the stock market since 2015, it operates in the world of health and science. It has 26 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
There is $88.9M in the vault; even if every debt were paid off, $88.9M would remain.
Over the last 12 months, company executives reported 20 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $53.50 — 63% above today’s price.
A loss of $27.0M against $0 in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 8/100.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, VTVT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VTVT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (56/100) says the stock isn’t cheap.